Patients with presbyopia achieved visual acuity improvement with LNZ100 in the phase 3 CLARITY safety and efficacy trials, according to a press release from Lenz Therapeutics.
The CLARITY 1 and 2 trials investigated the eye drops LNZ100 (1.75% aceclidine) and LNZ101, another formulation of aceclidine, for the treatment of presbyopia. The trials included 1,059 patients aged 45 to 75 years who had a spherical equivalent refractive range between –4 D and +1 D. CLARITY 1 was brimonidine controlled, while CLARITY 2 was vehicle controlled.
The primary efficacy endpoint in both (Read more...)